Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide plus T/TP chemotherapy for first-line advanced triple-negative breast cancer
ChiCTR2300075789Phase 4Recruiting
- Sponsor
- China-Japan Friendship Hospital
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tucidinostat in triple-negative breast cancer (TNBC), sponsored by China-Japan Friendship Hospital. Primary endpoint: Progression-free survival. Started Apr 2023; status: recruiting.
02
Drugs
tucidinostat
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on ChiCTR2300075789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300075789.